Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results, Beats Expectations By $0.14 EPS

Vir Biotechnology (NASDAQ:VIR) released its quarterly earnings results on Wednesday. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14, FiscalAI reports. The business had revenue of $238.95 million for the quarter, compared to the consensus estimate of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. The business’s revenue was up 19582.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.80) EPS.

Here are the key takeaways from Vir Biotechnology’s conference call:

• Hepatitis delta efficacy data remained strong: In the 96-week SOLSTICE analysis, 88% of patients receiving elebsiran plus tobevibart achieved undetectable virus versus 53% with tobevibart alone, alongside durable ALT improvements and no treatment-related serious adverse events or discontinuations.
• Vir completed enrollment in all three registrational ECLIPSE studies, with topline data expected from ECLIPSE 1 in the fourth quarter of 2026 and ECLIPSE 2 and 3 in the first quarter of 2027. The company highlighted ECLIPSE 2’s bulevirtide-switch data as a potential launch differentiator.
• The oncology pipeline advanced rapidly following the Astellas collaboration, with VIR-5500 enrolling multiple monotherapy and combination expansion cohorts and potential phase III trials targeted for 2027. Additional data from HER2-targeted VIR-5818 are expected in the second half of 2026.
• Vir ended the quarter with approximately $1.01 billion in cash, cash equivalents, and investments after receiving $315 million from Astellas, extending projected cash runway into the second half of 2028.
• Management acknowledged ongoing senior leadership recruitment, including searches for a new chief medical officer and chief financial officer, while the company continues to manage simultaneous hepatitis delta and oncology development programs.

Vir Biotechnology Trading Down 0.7%

VIR traded down $0.06 on Wednesday, hitting $9.11. 1,444,865 shares of the company were exchanged, compared to its average volume of 2,542,792. The firm has a 50-day moving average price of $9.32 and a two-hundred day moving average price of $9.00. Vir Biotechnology has a twelve month low of $4.16 and a twelve month high of $11.66. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -2.91 and a beta of 1.66.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the sale, the director owned 21,216 shares of the company’s stock, valued at $200,491.20. This trade represents a 13.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in shares of Vir Biotechnology by 1.0% in the 2nd quarter. Rhumbline Advisers now owns 228,949 shares of the company’s stock valued at $1,154,000 after purchasing an additional 2,300 shares during the last quarter. Corient Private Wealth LLC grew its stake in shares of Vir Biotechnology by 1.0% during the fourth quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock worth $1,572,000 after purchasing an additional 2,515 shares in the last quarter. Focus Partners Wealth increased its holdings in Vir Biotechnology by 15.3% in the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after buying an additional 2,566 shares during the last quarter. LPL Financial LLC raised its stake in Vir Biotechnology by 7.2% in the fourth quarter. LPL Financial LLC now owns 38,750 shares of the company’s stock valued at $234,000 after buying an additional 2,600 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Vir Biotechnology by 1.5% during the 4th quarter. Deutsche Bank AG now owns 206,222 shares of the company’s stock worth $1,244,000 after acquiring an additional 3,118 shares in the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on VIR shares. Morgan Stanley lifted their target price on shares of Vir Biotechnology from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, June 11th. Leerink Partners raised their price target on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Finally, Wall Street Zen downgraded Vir Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.